Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / GRCL - Gracell to start testing CAR-T therapy in leukemia patients in China

GRCL - Gracell to start testing CAR-T therapy in leukemia patients in China

Gracell Biotechnologies Inc.
National Medical Products Administration in China has signed off Gracell Biotechnologies' ([[GRCL]] -2.1%) investigational new drug application to study GC019F, a FasTCAR-enabled chimeric antigen receptor ((CAR))-T therapy in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia.GC019F is manufactured on Gracell's FasTCAR technology platform, which significantly reduces manufacturing time from an industry norm of two to six weeks down to 22 to 36 hours.Last week, the company secured Medical Products Manufacturing Certificate for the production of CAR-T cell therapy for cancer treatment, in China.

For further details see:

Gracell to start testing CAR-T therapy in leukemia patients in China
Stock Information
Company Name: Gracell Biotechnologies Inc.
Stock Symbol: GRCL
Market: NASDAQ
Website: gracellbio.com
Menu
GRCL GRCL Quote GRCL Short GRCL News GRCL Articles GRCL Message Board
Get GRCL Alerts

News, Short Squeeze, Breakout and More Instantly...